Antares Vision SpA (AV) AI Stock Analysis

• Market Cap: €354.81M
• Dividend Yield: N/A
• Average Volume (3M): 124.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 7.94%
• EPS Growth: 91.30%
• Country: IT
• Employees: 1,120
• Sector: Industrials
• Sector Strength: 72
• Industry: Security & Protection Services
• EPS (TTM): N/A
• Shares Outstanding: 71,030,045
• 10 Day Avg. Volume: 84,173
• 30 Day Avg. Volume: 124,256
• PEG Ratio: 0.14
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 1.06
• P/FCF Ratio: 6.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €5.40
• Price Target Upside: 8.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: €5.00 ▲(0.00% Upside)

Antares Vision SpA's stock score is primarily influenced by financial challenges, including declining revenues and profitability issues, which are partially offset by positive technical indicators. The valuation is negatively impacted by a negative P/E ratio and lack of dividend yield.

Positive Factors

Recurring Revenue Stream

The recurring revenue from after-sales services provides a stable income source, enhancing financial predictability and supporting long-term growth.

Strategic Partnerships

Strategic partnerships can enhance product offerings and market reach, fostering innovation and competitive positioning in the industry.

Cash Flow Improvements

Improved cash flow management indicates better financial health, allowing for reinvestment in growth opportunities and operational stability.

Negative Factors

Declining Revenue

Declining revenue trends can hinder growth prospects and reflect challenges in maintaining market share or product demand.

Profitability Challenges

Sustained profitability issues can impact financial sustainability, limiting the ability to invest in new projects and technologies.

Operational Inefficiencies

Operational inefficiencies can lead to increased costs and reduced margins, affecting overall competitiveness and financial performance.

Antares Vision SpA Business Overview & Revenue Model

Company Description

Antares Vision SpA is an Italian technology company specializing in product and process traceability, particularly in the pharmaceutical, cosmetic, and food sectors. The company offers a range of solutions including serialization, aggregation, and inspection systems, as well as software platforms designed to enhance supply chain transparency and compliance with regulatory standards. Antares Vision is committed to ensuring product safety and quality, leveraging advanced technologies like artificial intelligence and the Internet of Things (IoT) to provide innovative solutions.

How the Company Makes Money

Antares Vision generates revenue primarily through the sale of its hardware and software solutions, including serialization and inspection systems. Key revenue streams include the initial sale of equipment, ongoing software licensing fees, and maintenance services. The company also benefits from long-term contracts with major pharmaceutical companies, which provide a steady income stream. Additionally, partnerships with industry leaders and participation in various supply chain projects enhance its market presence and contribute to its earnings. The increasing demand for traceability and compliance solutions in the pharmaceutical and food sectors further supports the company’s revenue growth.

Antares Vision SpA Financial Statement Overview

Summary

Antares Vision SpA faces financial challenges with declining revenues and profitability pressures. Improvements in cash flow management are noted, but operational inefficiencies and a need to strengthen the equity position remain critical.

Income Statement

Antares Vision SpA's revenue has shown a declining trend, decreasing from 2022 to 2024. The gross profit margin has improved marginally in 2024 compared to 2023, but the company has faced significant EBIT and net income losses in recent years, indicating challenges in profitability. The company needs to address its operational inefficiencies to stabilize its income statement.

Balance Sheet

The balance sheet shows a moderate level of debt relative to equity, with a debt-to-equity ratio suggesting manageable leverage. However, the declining stockholders' equity from 2022 to 2024 and the decrease in total assets indicate potential risks to financial stability. The equity ratio remains moderate, but the company should focus on strengthening its equity position.

Cash Flow

The cash flow statement shows a recovery in operating cash flow in 2024 compared to negative figures in previous years, indicating improvements in cash management. Free cash flow has also turned positive, suggesting better capital expenditure management. However, historical volatility in cash flows suggests that the company needs to maintain consistent cash generation to support operations and investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	210.96M	207.49M	210.02M	201.31M	179.13M	121.11M
Gross Profit	61.98M	147.11M	22.55M	155.08M	144.78M	93.32M
EBITDA	5.42M	13.94M	-68.77M	17.77M	33.36M	22.70M
Net Income	-9.78M	-18.77M	-99.65M	1.63M	12.40M	18.16M
Balance Sheet
Total Assets	378.34M	419.78M	436.44M	581.99M	507.61M	362.92M
Cash, Cash Equivalents and Short-Term Investments	49.07M	65.29M	56.61M	87.92M	118.48M	129.19M
Total Debt	140.03M	151.55M	163.99M	151.30M	145.20M	158.45M
Total Liabilities	243.63M	259.74M	268.72M	273.14M	235.21M	227.76M
Stockholders Equity	134.69M	159.84M	167.81M	308.75M	272.33M	134.83M
Cash Flow
Free Cash Flow	20.63M	33.18M	-23.99M	-28.07M	13.32M	9.12M
Operating Cash Flow	31.22M	43.80M	-6.79M	-10.47M	29.82M	16.06M
Investing Cash Flow	-4.57M	-6.34M	-9.99M	-22.14M	-136.76M	-54.84M
Financing Cash Flow	-22.05M	-22.91M	-3.07M	14.39M	88.37M	50.13M

Antares Vision SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:AV, the sentiment is Positive. The current price of 5 is above the 20-day moving average (MA) of 4.99, below the 50-day MA of 5.04, and above the 200-day MA of 4.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.03 is Neutral, neither overbought nor oversold. The STOCH value of 19.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:AV.

Antares Vision SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
AV	54 Neutral	€354.81M	-36.18	―	―	7.94%	91.30%
FDA	38 Underperform	€2.32M	-0.03	-51.46%	―	-27.40%	82.08%

Antares Vision SpA Corporate Events

Antares Vision and Fine Foods Extend Strategic Partnership for Technological Innovation

Antares Vision Group and Fine Foods Group have announced the continuation of their multi-year partnership, which focuses on technological innovation to enhance growth and competitiveness. This collaboration aims to ensure compliance with international traceability regulations, optimize production data management, and improve operational efficiency across the pharmaceutical, nutraceutical, and cosmetic sectors. The partnership underscores both companies’ commitment to quality, innovation, and sustainability, with Antares Vision providing scalable solutions that support Fine Foods in digitalization and regulatory compliance. This strategic alliance is expected to generate sustainable, long-term value for both companies and their clients.

Antares Vision Announces Completion of Dorado Demerger

Antares Vision S.p.A. announced the completion of a total demerger of Dorado S.r.l., resulting in the creation of two new entities, Auremis Holding S.r.l. and Mimas Holding S.r.l., which are controlled by Dorado’s shareholders. This restructuring maintains the existing shareholders’ agreement concerning the shares of Regolo S.p.A., which indirectly affects Antares Vision due to its control by Regolo. The demerger does not alter the ownership structure, with the parties retaining about 72% of Regolo’s share capital.

Antares Vision Announces Leadership Changes with New CEO Appointment

Antares Vision has announced the resignation of its CEO, Gianluca Mazzantini, as part of a consensual resolution agreement. Fabio Forestelli has been appointed as the new CEO, while Stefano De Rosa has been co-opted as an Executive Director. The company is focused on strengthening its market position and generating sustainable growth, with a renewed commitment to innovation and customer value.

Antares Vision Group and Guinea-Bissau Enhance Pharmaceutical Traceability

Antares Vision Group has partnered with Guinea-Bissau to implement a national pharmaceutical traceability system, marking a significant advancement in digital healthcare in West Africa. This collaboration includes expanding local pharmaceutical production capacities and extending traceability to the medical device sector, positioning Guinea-Bissau as a leader in digital healthcare within the ECOWAS region. The initiative, which will begin generating revenue in late 2025, aims to enhance patient safety and regulatory compliance through the National Drug Catalog and a robust inspection program to reduce illicit imports. The upcoming launch of the AVGroupHub digital platform will facilitate registration for all stakeholders, aligning with regulations effective in March 2026.

Crane NXT to Acquire Majority Stake in Antares Vision for Delisting

Antares Vision S.p.A. is set for a significant ownership change as Crane NXT, Co. plans to acquire a 58.7% stake through a new joint-stock company, BidCo, with the aim of delisting Antares Vision from Euronext Milan. This acquisition involves a series of agreements, including a sale and purchase agreement and an investment agreement, which outline the transfer of shares, management commitments, and future corporate governance. The move is expected to impact Antares Vision’s market positioning and operations, potentially influencing stakeholders involved in the company’s governance and strategic direction.

Antares Vision Announces Change in Board Member Status

Antares Vision S.p.A., a company listed on the Italian stock exchange, has announced a change in the status of one of its board members. Lawyer Vittoria Giustiniani has lost her independence requirements due to her association with BonelliErede, a law firm involved in a recent acquisition of a controlling stake in Antares Vision by Crane NXT Co. This change does not affect the company’s compliance with regulations regarding the number of independent directors on its board.

Antares Vision Releases Half-Yearly Financial Report for 2025

Antares Vision S.p.A. has announced the availability of its Half-Yearly Financial Report for the period ending 30 June 2025. The report, approved by the Board of Directors, is accessible to the public through the company’s registered office, the ‘1INFO’ storage mechanism, and the company’s website. This release underscores the company’s commitment to transparency and provides stakeholders with insights into its financial performance for the first half of the year.

Antares Vision Group Reports Strong Order Growth and Profitability in 1H 2025

Antares Vision Group reported a 14% year-over-year increase in orders for the first half of 2025, with significant growth in the Americas and Asia & Oceania, despite geopolitical tensions affecting the second quarter. The company doubled its adjusted EBITDA to €7.3 million and maintained net debt levels, while its L5 Government Solutions business showed promising prospects in Africa and the Middle East, positioning it as a growth driver for future profitability.

Antares Vision Group Partners with Gambia’s MCA for Pharmaceutical Traceability

Antares Vision Group has signed a strategic agreement with the Medicines Control Agency (MCA) of Gambia to implement DIAMIND Government Solutions, enhancing pharmaceutical traceability and regulatory oversight in the country. This initiative, starting in late 2025, aims to secure Gambia’s pharmaceutical supply chain and integrate digital systems into MCA’s operations, with support from the Africa Agenda Network. The project is expected to improve drug safety, transparency, and regulatory efficiency, aligning with Gambia’s healthcare transformation goals and expanding Antares Vision Group’s presence in the African market.